QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
QQQ   424.38 (-0.34%)
AAPL   166.93 (-0.64%)
MSFT   407.47 (-1.06%)
META   505.19 (+2.23%)
GOOGL   156.27 (+0.51%)
AMZN   179.97 (-0.72%)
TSLA   150.22 (-3.36%)
NVDA   846.94 (+0.78%)
AMD   154.39 (+0.24%)
NIO   4.04 (+3.32%)
BABA   68.95 (+0.19%)
T   16.21 (+0.56%)
F   12.03 (-0.08%)
MU   112.45 (-3.34%)
GE   155.27 (-0.26%)
CGC   7.81 (+20.34%)
DIS   113.14 (+0.18%)
AMC   2.92 (-2.01%)
PFE   25.31 (-0.43%)
PYPL   62.43 (-1.31%)
XOM   118.53 (-0.08%)
Free Trial
Top-Rated StocksTop-Rated
NASDAQ:ICLR

ICON Public (ICLR) Stock Price, News & Analysis

→ Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad)
Free ICLR Stock Alerts
$294.37
+2.35 (+0.80%)
(As of 01:12 PM ET)
Compare
Today's Range
$287.90
▼
$298.99
50-Day Range
$273.84
▼
$340.00
52-Week Range
$181.92
▼
$344.77
Volume
272,906 shs
Average Volume
540,053 shs
Market Capitalization
$24.29 billion
P/E Ratio
39.89
Dividend Yield
N/A
Price Target
$319.45
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media

ICON Public MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
7.1% Upside
$319.45 Price Target
Short Interest
Healthy
1.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of ICON Public in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.35%
From $14.40 to $16.61 Per Share

Overall MarketRank™

New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.84 out of 5 stars

Medical Sector

188th out of 914 stocks

Commercial Physical Research Industry

5th out of 11 stocks

See Top Rated MarketRank™ Stocks Here
ICLR stock logo

About ICON Public Stock (NASDAQ:ICLR)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

ICLR Stock Price History

ICLR Stock News Headlines

April 18, 2024 | americanbankingnews.com
ICON Public Limited (NASDAQ:ICLR) Short Interest Update
April 17, 2024 | americanbankingnews.com
ICON Public (ICLR) to Release Quarterly Earnings on Wednesday
April 18, 2024 | Darwin (Ad)
2024's Must-Have Guide: Master Crypto Investment Today
The cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)
April 16, 2024 | benzinga.com
Looking At Icon's Recent Unusual Options Activity
April 12, 2024 | benzinga.com
Here's How Much You Would Have Made Owning Icon Stock In The Last 20 Years
April 9, 2024 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and Neurocrine (NBIX)
April 9, 2024 | markets.businessinsider.com
Wawanesa Insurance Announces Wildfire Prevention Grant Recipients
April 3, 2024 | businesswire.com
ICON Announces CFO Transition
April 18, 2024 | Crypto Swap Profits (Ad)
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
April 1, 2024 | msn.com
Logo vs icon vs symbol: all the logo terms you need to know
March 31, 2024 | finance.yahoo.com
A Look At The Intrinsic Value Of ICON Public Limited Company (NASDAQ:ICLR)
March 30, 2024 | yahoo.com
ICON Park restaurant will offer weekend brunches
March 29, 2024 | finance.yahoo.com
ICON Public Limited Company (ICLR) Improved by 15% in Q4
March 25, 2024 | businesswire.com
ICON plc Schedules First Quarter 2024 Earnings Conference Call
March 14, 2024 | msn.com
ICON announces new multi-story 3D printer
March 14, 2024 | finance.yahoo.com
ICON (NASDAQ:ICLR) shareholders have earned a 20% CAGR over the last five years
March 9, 2024 | cnn.com
ICON Plc
February 26, 2024 | ca.finance.yahoo.com
ICLR Apr 2024 430.000 put
February 26, 2024 | businesswire.com
ICON plc to Present at Upcoming Investor Conferences
February 24, 2024 | finance.yahoo.com
Earnings Beat: ICON Public Limited Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
February 23, 2024 | finance.yahoo.com
ICON Public Limited Company (NASDAQ:ICLR) Q4 2023 Earnings Call Transcript
February 23, 2024 | finance.yahoo.com
ICON Full Year 2023 Earnings: EPS Beats Expectations
February 22, 2024 | seekingalpha.com
ICON Public Limited Company 2023 Q4 - Results - Earnings Call Presentation
February 21, 2024 | finance.yahoo.com
Icon PLC (ICLR) Q4 Earnings Surpass Estimates
February 21, 2024 | finanznachrichten.de
ICON plc: ICON Reports Fourth Quarter and Full Year 2023 Results
February 21, 2024 | finance.yahoo.com
ICON Reports Fourth Quarter and Full Year 2023 Results
February 21, 2024 | businesswire.com
ICON Reports Fourth Quarter and Full Year 2023 Results
See More Headlines
Receive ICLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ICON Public and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
4/18/2024
Next Earnings (Confirmed)
4/24/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:ICLR
CUSIP
N/A
CIK
1060955
Web
www.iconplc.com
Phone
(531) 291-2000
Fax
353-1247-6260
Employees
41,100
Year Founded
1990

Price Target and Rating

Average Stock Price Target
$319.45
High Stock Price Target
$367.00
Low Stock Price Target
$220.00
Potential Upside/Downside
+9.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$7.38
Trailing P/E Ratio
39.57
Forward P/E Ratio
20.28
P/E Growth
1.39
Net Income
$612.34 million
Net Margins
7.54%
Pretax Margin
7.69%
Return on Equity
11.42%
Return on Assets
5.95%

Debt

Debt-to-Equity Ratio
0.40
Current Ratio
1.21
Quick Ratio
1.21

Sales & Book Value

Annual Sales
$8.12 billion
Price / Sales
2.97
Cash Flow
$19.33 per share
Price / Cash Flow
15.11
Book Value
$112.02 per share
Price / Book
2.61

Miscellaneous

Outstanding Shares
82,500,000
Free Float
46,197,000
Market Cap
$24.09 billion
Optionable
Optionable
Beta
1.15

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover
These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Dr. John Climax Ph.D. (Age 71)
    Founder & Independent Non-Executive Director
    Comp: $90k
  • Mr. Brendan Brennan (Age 45)
    Chief Financial Officer
    Comp: $1.07M
  • Dr. Steven A. Cutler MBA (Age 64)
    Ph.D., CEO & Director
    Comp: $2.54M
  • Jonathan Andrew Curtain (Age 48)
    Senior Vice President of Corporate & Commercial Finance
  • Mr. Thomas N. O'Leary
    Chief Information Officer
  • Mr. Diarmaid Cunningham (Age 49)
    Chief Administrative Officer, General Counsel & Company Secretary
  • Ms. Niamh Murphy
    Director of Corporate Communications
  • Mr. David Green
    Vice President of Marketing
  • Mr. Joe Cronin
    Chief Human Resources Officer
  • Mr. Simon Holmes (Age 57)
    President of Corporate Investments & Partnerships

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

Should I Buy ICON Public Stock? ICLR Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • ICON Public has shown consistent revenue growth over recent quarters, indicating a strong financial performance.
  • The company has a healthy return on equity of 11.42%, showcasing efficient utilization of shareholder funds.
  • Institutional investors have been increasing their stakes in ICON Public, reflecting confidence in the company's future prospects.
  • ICON Public's net margin of 7.54% demonstrates effective cost management and profitability.
  • Analysts expect ICON Public to post a solid EPS of 14.4 for the current fiscal year, suggesting potential for earnings growth.

Cons

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • Despite strong financial metrics, the stock price of ICON Public may be overvalued based on current market conditions.
  • There could be regulatory risks associated with the clinical research industry that may impact ICON Public's operations and profitability.
  • Competition in the clinical research sector is intense, which could potentially affect ICON Public's market share and growth prospects.
  • Market volatility and economic uncertainties may pose challenges to ICON Public's stock performance in the short term.
  • Investors should carefully monitor any changes in industry trends and regulations that could impact ICON Public's business model and revenue streams.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, April 13, 2024. Please send any questions or comments about these ICON Public pros and cons to contact@marketbeat.com.

ICLR Stock Analysis - Frequently Asked Questions

Should I buy or sell ICON Public stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ICON Public in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ICLR shares.
View ICLR analyst ratings or view top-rated stocks.

What is ICON Public's stock price target for 2024?

8 analysts have issued 1-year price targets for ICON Public's shares. Their ICLR share price targets range from $220.00 to $367.00. On average, they expect the company's share price to reach $319.45 in the next year. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for ICLR or view top-rated stocks among Wall Street analysts.

How have ICLR shares performed in 2024?

ICON Public's stock was trading at $283.07 on January 1st, 2024. Since then, ICLR shares have increased by 5.3% and is now trading at $298.21.
View the best growth stocks for 2024 here.

Are investors shorting ICON Public?

ICON Public saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 1,390,000 shares, a decline of 6.7% from the March 15th total of 1,490,000 shares. Based on an average trading volume of 551,500 shares, the short-interest ratio is currently 2.5 days. Currently, 1.7% of the shares of the company are short sold.
View ICON Public's Short Interest.

When is ICON Public's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our ICLR earnings forecast.

How can I listen to ICON Public's earnings call?

ICON Public will be holding an earnings conference call on Thursday, April 25th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were ICON Public's earnings last quarter?

ICON Public Limited (NASDAQ:ICLR) issued its quarterly earnings results on Wednesday, February, 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.27 by $0.13. The medical research company earned $2.07 billion during the quarter, compared to analysts' expectations of $2.08 billion. ICON Public had a trailing twelve-month return on equity of 11.42% and a net margin of 7.54%.

What ETFs hold ICON Public's stock?

ETFs with the largest weight of ICON Public (NASDAQ:ICLR) stock in their portfolio include Motley Fool Global Opportunities ETF (TMFG), iShares MSCI Ireland ETF (EIRL), VanEck Biotech ETF (BBH), Janus Henderson US Sustainable Equity ETF (SSPX), VictoryShares Nasdaq Next 50 ETF (QQQN), Invesco ESG NASDAQ Next Gen 100 ETF (QQJG), Harbor Health Care ETF (MEDI) and BNY Mellon Sustainable International Equity ETF (BKIS).

What guidance has ICON Public issued on next quarter's earnings?

ICON Public updated its FY 2024 earnings guidance on Thursday, April, 18th. The company provided earnings per share (EPS) guidance of 14.500-15.300 for the period, compared to the consensus earnings per share estimate of 14.940. The company issued revenue guidance of $8.4 billion-$8.8 billion, compared to the consensus revenue estimate of $8.6 billion.

What is Steve Cutler's approval rating as ICON Public's CEO?

147 employees have rated ICON Public Chief Executive Officer Steve Cutler on Glassdoor.com. Steve Cutler has an approval rating of 63% among the company's employees. This puts Steve Cutler in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of ICON Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ICON Public investors own include Pfizer (PFE), Gilead Sciences (GILD), Visa (V), NVIDIA (NVDA), CVS Health (CVS), UnitedHealth Group (UNH), Alibaba Group (BABA), Walt Disney (DIS), Home Depot (HD) and Johnson & Johnson (JNJ).

Who are ICON Public's major shareholders?

ICON Public's stock is owned by many different retail and institutional investors. Top institutional shareholders include Cullen Investment Group LTD. (0.01%), Steph & Co. (0.00%), NBC Securities Inc. (0.00%), GAMMA Investing LLC (0.00%) and Riverview Trust Co (0.00%).

How do I buy shares of ICON Public?

Shares of ICLR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does ICON Public have any subsidiaries?
The following companies are subsidiares of ICON Public: Addplan Inc., Aptiv Solutions, Barton & Polansky Associates Inc., Beacon Bioscience Inc., BeijingWits Medical Consulting Ltd., C4 MedSolutions LLC, CHC Group LLC, CRN Holdings LLC, CRN North America LLC, Clinical Research Management, Clinical Resource Network LLC, Complete Healthcare Communications LLC, Complete Publication Solutions LLC, Cross Country Healthcare - Clinical Trial Services, DOCS Global Inc., DOCS Insourcing B.V., DOCS International B.V., DOCS International Belgium N.V., DOCS International Finland Oy, DOCS International France S.A.S., DOCS International Germany GmbH, DOCS International Nordic Countries A/S, DOCS International Poland Sp. z o.o., DOCS International Sweden AB, DOCS International Switzerland GmbH, DOCS International UK Limited, DOCS Italia S.R.L., DOCS Resourcing Limited, DOCS Ukraine LLC, Firecrest Clinical Ltd, Global Pharmaceutical Strategies Group LLC, ICON (LR) Limited, ICON Ankara Klinik Arastirma Dis Ticaret Anonim Sirketi, ICON CRO Malaysia SDN. BHD., ICON Chile Limitada, ICON Clinical International Unlimited Company, ICON Clinical Research (Beijing No.2) Co. Ltd, ICON Clinical Research (Beijing) Co. Ltd, ICON Clinical Research (Canada) Inc., ICON Clinical Research (New Zealand) Limited, ICON Clinical Research (Pte) Limited, ICON Clinical Research (Rus) LLC, ICON Clinical Research (Switzerland) GmbH, ICON Clinical Research (Thailand) Limited, ICON Clinical Research (U.K.) Limited, ICON Clinical Research Austria GmbH, ICON Clinical Research EOOD, ICON Clinical Research España S.L., ICON Clinical Research GmbH, ICON Clinical Research Hong Kong Limited, ICON Clinical Research India Private Limited, ICON Clinical Research Israel Limited, ICON Clinical Research Korea Yuhan Hoesa, ICON Clinical Research Korea Yuhan Hoesa (ICON Clinical Research Korea Ltd.), ICON Clinical Research LLC, ICON Clinical Research Limited, ICON Clinical Research México S.A. de C.V., ICON Clinical Research PTY Limited, ICON Clinical Research Perú S.A., ICON Clinical Research Property Development (Ireland) Limited, ICON Clinical Research S.A., ICON Clinical Research S.R.L., ICON Clinical Research SARL, ICON Clinical Research Services Philippines Inc., ICON Clinical Research Slovakia s.r.o., ICON Clinical Research Sp. z o.o., ICON Clinical Research Taiwan Limited, ICON Clinical Research d.o.o. Beograd, ICON Clinical Research s.r.o., ICON Contracting Solutions Holdings B.V., ICON Development Solutions Limited, ICON Early Phase Services LLC, ICON Global Treasury Limited, ICON Government and Public Health Solutions Inc., ICON Government and Public Health Solutions Inc. (formerly Clinical Research Management (ClinicalRM)), ICON Holdings Clinical Research International Limited, ICON Holdings Unlimited Company, ICON Investments Five Unlimited Company, ICON Investments Four Unlimited Company, ICON Investments Limited, ICON Japan K.K., ICON Klinikai Kutató Korlátolt Felelősségű Társaság, ICON Klinikai Kutató Korlátolt Felelősségű Társaság (ICON Clinical Research Limited Liability Company), ICON Laboratory Services Inc., ICON Pesquisas Clínicas LTDA., ICON US Holdings Inc., Improving Treatments Limited, Ispitivanja ICON d.o.o, Ispitivanja ICON d.o.o (ICON Research Ltd.), MMMM Consulting LLC, MMMM Group LLC, Managed Care Strategic Solutions L.L.C., Mapi Développement SAS, Mapi Group, Mapi Life Sciences Canada Inc., Mapi Life Sciences UK Limited, Mapi Research Trust, Mapi Research Trust*, Mapi SAS, Mapi USA Inc., MeDiNova Investigacion y Desarrollo S.L., MeDiNova Lakeside Clinical Research Limited, MeDiNova Limited, MeDiNova Merc (UK) Limited, MeDiNova Merc Clinical Research (SA) Pty Limited, MeDiNova Research, MedPass International, MediMedia Pharma Solutions, Molecular MD Corp., MolecularMD, Oxford Outcomes Limited, Oxford Outcomes Ltd, PMG Research, PMG Research Inc., PMG Research of Bristol LLC, PMG Research of Charleston LLC, PMG Research of Charlotte LLC, PMG Research of Christie Clinic LLC, PMG Research of Hickory LLC, PMG Research of Raleigh LLC, PMG Research of Rocky Mount LLC, PMG Research of Salisbury LLC, PMG Research of Wilmington LLC, PMG Research of Winston-Salem LLC, PRA Health Sciences, Pacific Research Associates Inc., Prevalere Life Sciences Inc., PriceSpective, Pricespective LLC, PubsHub LLC, Symphony Clinical Research Sp. z o.o., Timaq Medical Imaging, UCT (U.S.) Inc, VSK (Kenilworth) Limited, and Veeda Laboratories Ltd..
Read More
This page (NASDAQ:ICLR) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
The Next Nvidia?
InvestorPlace
Options trading has suddenly become more reliable.
Eagle Publishing
Top 5 AI Stocks to Buy for 2024
Market Moving Trends
Urgent alert: open this for a huge profit potential
Timothy Sykes
AI healthcare stock poised for 36,996% growth?
Behind the Markets